Choroid plexus controls brain availability of anti-HIV nucleoside analogs via pharmacologically inhibitable organic anion transporters

AIDS

Volumn 17, Issue 10, 2003, Pages 1473-1485

  Strazielle, Nathalie ^a   Belin, Marie Françoise ^a   Ghersi Egea, Jean François ^a  

^a INSERM   (France)

Author keywords

AIDS; Antiretroviral nucleoside analog; Benzbromarone; Blood brain barrier; Blood cerebrospinal fluid barrier; Choroid plexus; Solute carrier

Indexed keywords

DIDANOSINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; ORGANIC ANION TRANSPORTER; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANION TRANSPORT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD CEREBROSPINAL FLUID BARRIER; CHOROID PLEXUS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TRANSPORT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IN VITRO STUDY; IN VIVO STUDY; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FAMILY; RAT; VIRUS LOAD; VIRUS RESISTANCE;

EID: 0042368706     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200307040-00008     Document Type: Article

References (62)

1. Atwood WJ, Berger JR, Kaderman R, Tornatore CS, Major EO. Human immunodeficiency virus type 1 infection of the brain. Clin Microbiol Rev 1993, 6:339-366.
2. Price RW. Neurological complications of HIV infection. Lancet 1996, 348:445-452.
3. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992, 42:1736-1739.
4. Gray F, Scaravilli F, Everall I, Chretien F, An S, Boche D, et al. Neuropathology of early HIV-1 infection. Brain Pathol 1996, 6:1-15.
5. Hughes ES, Bell JE, Simmonds P. Investigation of the dynamics of the spread of human immunodeficiency virus to brain and other tissues by evolutionary analysis of sequences from the p17gag and env genes. J Virol 1997, 71:1272-1280.
6. Koison DL, Gonzalez-Scarano F. HIV and HIV dementia. J Clin Invest 2000, 106:11-13.
7. Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 2000, 14:1949-1954.
8. Lanier ER, Sturge G, McClernon D, Brown S, Halman M, Sacktor N, et al. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with abacavir. AIDS 2001, 15:747-751.
9. Davson H, Segal MB. Physiology of the CSF and the Blood-Brain Barriers. Boca Raton, New York, London, Tokyo: CRC Press; 1996.
10. Burger DM, Meenhorst PL, Beijnen JH. Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents. Pharm World Sci 1995, 17:25-30.
11. Groothuis DR, Levy RM. The entry of antiviral and antiretroviral drugs into the central nervous system. J Neurovirol 1997, 3:387-400.
12. Strazielle N, Ghersi-Egea JF. Choroid plexus in the central nervous system: biology and physiopathology. J Neuropathol Exp Neurol 2000, 59:561-574.
13. Schaner ME, Gerstin KM, Wang J, Giacomini KM. Mechanisms of transport of nucleosides and nucleoside analogues in choroid plexus. Adv Drug Deliv Rev 1999, 39:51-62.
14. Thomas SA, Segal MB. The passage of azidodeoxythymidine into and within the central nervous system: does it follow the parent compound, thymidine? J Pharmacol Exp Ther 1997, 281:1211-1218.
15. Suzuki H, Terasaki T, Sugiyama Y. Role of efflux transport across the blood-brain and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system. Adv Drug Deliv Rev 1997, 25:257-285.
16. Strazielle N, Ghersi-Egea JF. Demonstration of a coupled metabolism-efflux process at the choroid plexus as a mechanism of brain protection toward xenobiotics. J Neurosci 1999, 19:6275-6289.
17. Gao B, Meier PJ. Organic anion transport across the choroid plexus. Microsc Res Tech 2001, 52:60-64.
18. Ghersi-Egea JF, Strazielle N. Brain drug delivery, drug metabolism, and multidrug resistance at the choroid plexus. Microsc Res Tech 2001, 52:83-88.
19. Falangola MF, Hanly A, Galvao-Castro B, Petito CK. HIV infection of human choroid plexus: a possible mechanism of viral entry into the CNS. J Neuropathol Exp Neurol 1995, 54:497-503.
20. Chen H, Wood C, Petito CK. Comparisons of HIV-1 viral sequences in brain, choroid plexus and spleen: potential role of choroid plexus in the pathogenesis of HIV encephalitis. J Neurovirol 2000, 6:498-506.
21. Liu Y, Tang XP, McArthur JC, Scott J, Gartner S. Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol 2000, 6 Suppl 1:S70-81.
22. Sei S, Stewart SK, Farley M, Mueller BU, Lane JR, Robb ML, et al. Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. J Infect Dis 1996, 174:1200-1206.
23. Di Stefano M, Monno L, Fiore JR, Angarano G. In vivo evidence of HIV-1 productive infection in cerebrospinal fluid of patients with HIV-1 encephalitis. AIDS 1997, 11:133-135.
24. Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 1997, 42:679-688.
25. Cinque P, Vago L, Ceresa D, Mainini F, Terreni MR, Vagani A, et al. Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS 1998, 12:389-394.
26. Martin C, Albert J, Hansson P, Pehrsson P, Link H, Sonnerborg A. Cerebrospinal fluid mononuclear cell counts influence CSF HIV-1 RNA levels. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 17:214-219.
27. Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 1997, 175:963-966.
28. Morris L, Silber E, Sonnenberg P, Eintracht S, Nyoka S, Lyons SF, et al. High human immonodeficiency virus type 1 RNA load in the cerebrospinal fluid from patients with lymphocytic meningitis. J Infect Dis 1998, 177:473-476.
29. Ghersi-Egea JF, Finnegan W, Chen JL, Fenstermacher JD. Rapid distribution of intraventricularly administered sucrose into cerebrospinal fluid cisterns via subarachnoid velae in rat. Neuroscience 1996, 75:1271-1288.
30. Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA. Evidence for a 'paravascular' fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res 1985, 326:47-63.
31. Cunningham AL, Naif H, Saksena N, Lynch G, Chang J, Li S, et al. HIV infection of macrophages and pathogenesis of AIDS dementia complex: interaction of the host cell and viral genotype. J Leukoc Biol 1997, 62:117-125.
32. Groschel B, Himmel N, Cinatl J, Perigaud C, Gosselin G, Imbach JL, et al. ddC- and 3TC-bis(SATE) monophosphate prodrugs overcome cellular resistance mechanisms to HIV-1 associated with cytidine kinase deficiency. Nucleosides Nucleotides 1999, 18:921-926.
33. Siflinger-Birnboim A, Del Vecchio PJ, Cooper JA, Blumenstock FA, Shepard JM, Malik AB. Molecular sieving characteristics of the cultured endothelial monolayer. J Cell Physiol 1987, 132:111-117.
34. Welch K, Sadler K. Permeability of the choroid plexus of the rabbit to several solutes. Am J Physiol 1966, 210:652-660.
35. Fenstermacher JD. The pharmacology of the blood-brain barrier. In: Neuwelt E (editor): Implications of the Blood-Brain Barrier and its Manipulation. New York: Plenum; 1989, pp. 137-155.
36. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
37. Tsukita S, Furuse M. Occludin and claudins in tight-junction strands: leading or supporting players? Trends Cell Biol 1999, 9:268-273.
38. Lippoldt A, Liebner S, Andbjer B, Kalbacher H, Wolburg H, Haller H, et al. Organization of choroid plexus epithelial and endothelial cell tight junctions and regulation of claudin-1, -2 and -5 expression by protein kinase C. Neuroreport 2000, 11:1427-1431.
39. Zimmerman TP, Mahony WB, Prus KL. 3′-azido-3′-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem 1987, 262:5748-5754.
40. Hedaya MA, Sawchuk RJ. Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit. J Pharm Sci 1989, 78:716-722.
41. Hedaya MA, Elmquist WF, Sawchuk RJ. Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. Pharm Res 1990, 7:411-417.
42. Pritchard JB, Sweet DH, Miller DS, Walden R. Mechanism of organic anion transport across the apical membrane of choroid plexus. J Biol Chem 1999, 274:33382-33387.
43. Harouse JM, Wroblewska Z, Laughlin MA, Hickey WF, Schonwetter BS, Gonzalez-Scarano F. Human choroid plexus cells can be latently infected with human immunodeficiency virus. Ann Neurol 1989, 25:406-411.
44. Bagasra O, Lavi E, Bobroski L, Khalili K, Pestaner JP, Tawadros R, et al. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 1996, 10:573-585.
45. Blaney SM, Daniel MJ, Harker AJ, Godwin K, Balis FM. Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates. Antimicrob Agents Chemother 1995, 39:2779-2782.
46. Foudraine NA, Hoetelmans RM, Lange JM, de Wolf F, van Benthem BH, Maas JJ, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998, 351:1547-1551.
47. Rolinski B, Bogner JR, Sadri I, Wintergerst U, Goebel FD. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15:192-197.
48. Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, Young JD. Transport of antiviral 3′-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol 2001, 18:161-167.
49. Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 1997, 41:1082-1093.
50. McDowell JA, Chittick GE, Ravitch JR, Polk RE, Kerkering TM, Stein DS. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999, 43:2855-2861.
51. Thomas SA, Bye A, Segal MB. Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid. J Pharmacol Exp Ther 2001, 298:947-953.
52. Takasawa K, Terasaki T, Suzuki H, Ooie T, Sugiyama Y. Distributed model analysis of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. J Pharmacol Exp Ther 1997, 282:1509-1517.
53. Galinsky RE, Hoesterey BL, Anderson BD. Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. Life Sci 1990, 47:781-788.
54. Wang Y, Sawchuk RJ. Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. J Pharm Sci 1995, 84:871-876.
55. Sekine T, Cha SH, Endou H. The multispecific organic anion transporter (OAT) family. Pflugers Arch 2000, 440:337-350.
56. Ghersi-Egea JF, Strazielle N. Choroid plexus transporters for drugs and other xenobiotics. J Drug Target 2002, 10:353-357.
57. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood- cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 1999, 96:3900-3905.
58. Wada S, Tsuda M, Sekine T, Cha SH, Kimura M, Kanai Y, et al. Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J Pharmacol Exp Ther 2000, 294:844-849.
59. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 2002, 300:918-924.
60. Nagata Y, Kusuhara H, Endou H, Sugiyama Y. Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol 2002, 61:982-988.
61. Cretton EM, Schinazi RF, McClure HM, Anderson DC, Sommadossi JP. Pharmacokinetics of 3′-azido-3′-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. Antimicrob Agents Chemother 1991, 35:801-807.
62. Petty BG, Kornhauser DM, Lietman PS. Zidovudine with probenecid: a warning. Lancet 1990, 335:1044-1045.